Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled …
R Minutolo, ME Liberti, V Simeon… - Clinical Kidney …, 2024 - academic.oup.com
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease
JT Ha, S Hiremath, M Jun, SC Green… - NEJM …, 2024 - evidence.nejm.org
Background Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
VH Haase - Kidney international supplements, 2021 - Elsevier
Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …
new class of orally administered drugs currently in late-stage global clinical development for …
Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
B Wang, Q Yin, YC Han, M Wu, ZL Li, Y Tu, L Zhou… - Renal failure, 2020 - Taylor & Francis
Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-
class new generation drugs for renal anemia. This extensive meta-analysis of randomized …
class new generation drugs for renal anemia. This extensive meta-analysis of randomized …
Hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with renal anemia: a meta-analysis of randomized trials
T Wen, X Zhang, Z Wang, R Zhou - Nephron, 2020 - karger.com
Background: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new
class of treatment for renal anemia in patients with chronic kidney disease (CKD). This meta …
class of treatment for renal anemia in patients with chronic kidney disease (CKD). This meta …
[HTML][HTML] Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or …
N Damarlapally, V Thimmappa, H Irfan, M Sikandari… - Cureus, 2023 - ncbi.nlm.nih.gov
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …
Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta‐analysis including 13,146 …
H Chen, Q Cheng, J Wang, X Zhao… - Journal of clinical …, 2021 - Wiley Online Library
What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
D Chen, Y Niu, F Liu, Y Yang, X Wang, P Li… - Frontiers in …, 2023 - frontiersin.org
Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors
M Sugahara, T Tanaka, M Nangaku - Pharmacology & Therapeutics, 2022 - Elsevier
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …
Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis
Q Zheng, Y Wang, H Yang, L Sun, P Zhang… - American Journal of …, 2023 - Elsevier
Rationale & Objective Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are
novel, orally administered agents for anemia management in chronic kidney disease (CKD) …
novel, orally administered agents for anemia management in chronic kidney disease (CKD) …
相关搜索
- kidney disease meta analysis
- kidney disease efficacy and safety
- hydroxylase inhibitors meta analysis
- efficacy and safety meta analysis
- anemia in patients meta analysis
- hydroxylase inhibitors safety and efficacy
- hydroxylase inhibitors patients with ckd
- safety and efficacy renal patients
- kidney disease hydroxylase inhibitors
- kidney disease hif phis
- kidney disease comparison of outcomes
- adverse effects meta analysis
- hydroxylase inhibitors anemia management
- kidney disease anemia management
- patients with ckd meta analysis
- dialysis patients meta analysis